01—Abstract
Summary
Summary of the 10-K/A filed June 6, 1996. Cited figures are marked; the original filing is the authoritative source.
This filing is a Form 10-K/A from Biogen, Inc. (BIIB), dated June 6, 1996, covering fiscal year 1995.
The excerpt contains only the cover page and Part IV (Exhibits and Reports on Form 8-K). It does not include the financial statements, MD&A, or business discussion. Those are incorporated by reference from the 1995 Annual Report to Shareholders (Exhibit 13.0), which is not part of this excerpt, so revenue, net income, R&D spending, and cash position cannot be assessed from it.
The cover page reports about 15,099,229 common shares outstanding as of January 31, 1996, and an aggregate market value held by non-affiliates of approximately $303.6 milliona, based on the Nasdaq National Market closing price on that date. The stated 1996 annual meeting date was May 22, 1996. No Form 8-K reports were filed in the fourth quarter of 1995.
The exhibit list shows a heavy reliance on collaborations and licensing. Several agreements were entered into in late 1995 with Eisai, Zenyaku Kogyo, and Genentech, and there are continuing arrangements with SmithKline Beecham, Seikagaku, and Mitsubishi Chemical.
Many of these agreements carry confidential treatment requests, so their economic terms are not disclosed in this filing. Investors would need the full annual report and the underlying agreements to evaluate the company's financial position and partnership economics.
02—Key points
Key Highlights
- Filing is a Form 10-K/A for fiscal year ended December 31, 1995, filed June 6, 1996; the excerpt contains only the cover page and Part IV exhibit list.
- Approximately 15,099,229 common shares, no par value, were outstanding as of January 31, 1996.
- Aggregate market value of non-affiliate voting stock was about $303.6 million as of January 31, 1996, based on the Nasdaq National Market closing price.
- Financial statements and MD&A are incorporated by reference from the 1995 Annual Report to Shareholders (Exhibit 13.0), which is not included in this excerpt.
- Several late-1995 collaboration and license agreements were signed, including Eisai (December 11, 1995), Zenyaku Kogyo with Genentech (November 30, 1995), and an amendment to the Genentech Collaboration Agreement (November 30, 1995).
- Multiple partnership agreements, including those with SmithKline Beecham, Genentech, Seikagaku, and Mitsubishi Chemical, are on file, and several were granted or requested confidential treatment.
- No Form 8-K reports were filed during the fourth quarter of 1995; the 1996 annual shareholder meeting was scheduled for May 22, 1996.
03—Questions
Frequently Asked Questions
What is the company's financial performance for 1995?
This excerpt does not include financial statements. The 1995 results are contained in the Annual Report to Shareholders (Exhibit 13.0), which is incorporated by reference but not included here. Revenue, net loss, and cash figures must be obtained from that exhibit or the full filing.
How many shares are outstanding and what is the public float value?
As of January 31, 1996, there were 15,099,229 common shares outstanding. The aggregate market value of shares held by non-affiliates was approximately $303.6 million, based on the Nasdaq closing price on that date. Affiliate holdings are excluded from that figure.
What major agreements did the company enter into in late 1995?
The exhibit list includes a Collaborative Development Agreement and a License Agreement with Eisai Co., Ltd. (both dated December 11, 1995), a License Agreement, Development Agreement, Supply Agreement, and Termination Agreement involving Zenyaku Kogyo Co., Ltd. (dated November 30, 1995), and an amendment to the Genentech Collaboration Agreement (dated November 30, 1995). Economic terms are largely redacted under confidential treatment requests.
Why is key information missing from this filing?
The document is a 10-K/A amendment that contains the cover page and Part IV only. Part II financial information and Part I business information are incorporated by reference from the Annual Report to Shareholders and the proxy statement, which are not reproduced in this excerpt. Investors should review the complete original filing and Exhibit 13.0.
04—Continue